Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See
full details
.
I Agree
×
Join today and have your say! It’s FREE!
Join Now
Sign In
Become a member today, It's free!
We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.
Join Today
or
Sign in with existing account
Privacy Policy
|
Disclaimer
Sign In
Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Remember me
Forgot Password?
Sign In
or
Sign Up
Privacy Policy
|
Disclaimer
Please Try Again
{{ error }}
Send my password
Submit
Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.
Become a member today, It's free!
We will not release or resell your information to third parties without your permission.
Linking with Facebook:
Stockhouse membership requires an email address which must be shared by Facebook.
By default, joining or signing in using your Facebook account will work and the email address will be shared by Facebook automatically.
If you change your Facebook permissions to restrict Stockhouse from receiving your email while joining or signing in to Stockhouse then it will fail.
Please do not modify the permission settings during sign-in.
Sign in with Facebook
Return to Signup Options
Home
Community
Bullboards
Blogs
Groups
Messages
Markets
Stocks
TSX
TSXV
CSE
Cboe Canada
NASDAQ
NYSE
NYSE American
Cryptocurrency
Currencies
Market Movers
Bonds
News
Featured News
Trending News
Canadian Press Releases
US Press Releases
Video
Editorial
Thematic Insights
Independent Reports
Interviews
Buzz on the Bullboards
Portfolio
Watchlist
Portfolio
Showcase Companies
DealRoom
Quote
|
Bullboard
|
News
|
Opinion
|
Profile
|
Peers
|
Filings
|
Financials
|
Options
|
Price History
|
Ratios
|
Ownership
|
Insiders
|
Valuation
Bullboard - Stock Discussion Forum
Medipharm Labs Corp
T.LABS
Alternate Symbol(s):
MEDIF
Healthcare
Cannabis
MediPharm Labs Corp. is a Canada-based full-service pharmaceutical company. The Company specializes in the development and manufacture of purified, pharmaceutical-quality cannabis concentrates, active pharmaceutical ingredients (API) and advanced derivative products. Through its wholesale and white label platforms, the Company formulates, develops (including through sensory testing), processes,...
packages and distributes cannabis extracts and advanced cannabinoid-based products to domestic and international markets. It also provides GMP flower sourcing, packaging, and distribution services for select international clients. In addition, it cultivates cannabis to sell as dried flower, pre-roll and other cannabis products for the adult use and medical markets. It also sells metered dose inhalers and aerosol sublingual sprays. Through Harvest Medicine, it provides clinic services to Canadian patients requiring medical cannabis education and prescriptions.
see more
Join the community and start posting on the bullboards today. It's free.
You are already a member! Please enter your password to sign in.
Remember me
Forgot password?
Back
Submit
By providing my email, I consent to receiving messages from Stockhouse.
Create a portfolio watchlist today. It's free.
You are already a member! Please enter your password to sign in.
Remember me
Forgot password?
Back
Submit
By providing my email, I consent to receiving messages from Stockhouse.
Add To Watchlist
Bullboard (TSX:LABS)
New Post
View:
Posts & Comments
Threaded Posts
Prev
...
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
...
Next
(100)
•••
Solid1
X
View Profile
View Bullboard History
Comment by
Solid1
on Jul 02, 2024 3:32pm
RE:RE:RE:NDA/ANDA/505
The ANDA will be approved for a new therapy, and the NDA has already been mentioned several times, most recently in the last quarterly report
(131)
•••
QContinuum1
X
View Profile
View Bullboard History
Comment by
QContinuum1
on Jul 02, 2024 3:04pm
RE:RE:NDA/ANDA/505
ANDA is Epiodiolex, we know that. NDA is not and has not been mentioned.
(45)
•••
piduks
X
View Profile
View Bullboard History
Post by
piduks
on Jul 02, 2024 2:56pm
LOL, "hope" is bountiful but facts and details
are nil.
(264)
•••
alleyesonme
X
View Profile
View Bullboard History
Comment by
alleyesonme
on Jul 02, 2024 2:45pm
RE:Show me, with links from FDA website, those 3 filings
Partners/or clients...not medipharm labs...until they reveal who they are that's unavailable.
(100)
•••
Solid1
X
View Profile
View Bullboard History
Comment by
Solid1
on Jul 02, 2024 1:57pm
RE:NDA/ANDA/505
The ANDA and NDA filing was first mentioned in the Q3 2022 conference call. But then came the Jazz lawsuit, which presumably delayed everything, and finally the application was officially filed in
...more
(45)
•••
piduks
X
View Profile
View Bullboard History
Post by
piduks
on Jul 02, 2024 1:54pm
Show me, with links from FDA website, those 3 filings
by Medipharm Labs (ANDA, NDA, 505(b)2. FDA website link showing those 3 filings. They do NOT exist.
(131)
•••
QContinuum1
X
View Profile
View Bullboard History
Post by
QContinuum1
on Jul 02, 2024 1:29pm
NDA/ANDA/505
These three processes are different and I would advise anyone looking at the LABS investor deck or listening in on calls to go to the FDA website and take a look. I've discussed before that
...more
(100)
•••
Solid1
X
View Profile
View Bullboard History
Comment by
Solid1
on Jul 02, 2024 12:27pm
RE:RE:RE:RE:RE:ANDA Sep. 2023
That's it ! The patents only apply to the approved therapy but not to the active ingredients
(264)
•••
alleyesonme
X
View Profile
View Bullboard History
Comment by
alleyesonme
on Jul 02, 2024 12:18pm
RE:RE:RE:RE:ANDA Sep. 2023
What you speak of falls under the 505b2 application, an existing fda approved drug epidiolex(cannabidol a.k.a CBD) for a new indication, or dosage form..and thus, as I understand immune from existing
...more
(100)
•••
Solid1
X
View Profile
View Bullboard History
Comment by
Solid1
on Jul 02, 2024 11:31am
RE:RE:RE:ANDA Sep. 2023
A generic only confirmed the same effect as the original! If it is approved for a completely new therapy, there will be no lawsuits against it.
(100)
•••
Solid1
X
View Profile
View Bullboard History
Comment by
Solid1
on Jul 02, 2024 10:09am
RE:RE:ANDA Sep. 2023
Simply change the name after approval
(571)
•••
mdjbrown
X
View Profile
View Bullboard History
Comment by
mdjbrown
on Jul 02, 2024 10:04am
RE:ANDA Sep. 2023
Solid, the September 2023 was a typo, and should have read September 2022. Why the company did not issue a correction is beyond me, but the press release was made public on August 1, 2023 which
...more
(131)
•••
QContinuum1
X
View Profile
View Bullboard History
Comment by
QContinuum1
on Jul 02, 2024 9:48am
RE:ANDA Sep. 2023
The ANDA was confirmed (via Strachan on a recent CC) as being associated with Epidiolex. If LABS has partnered with a pharma company that has NOT settled the lawsuit, then 10 months can become
...more
(264)
•••
alleyesonme
X
View Profile
View Bullboard History
Comment by
alleyesonme
on Jul 02, 2024 9:27am
RE:ANDA Sep. 2023
https://stockhouse.com/news/press-releases/2023/08/01/medipharm-labs-makes-first-delivery-of-cannabis-clinical-trial-material-to-us
Prev
...
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
...
Next
Thank You
Your Report has been submitted.
Report Abusive Content
×
Close
Sign up to get access
You are already a member! Please enter your password to sign in.
Remember me
Forgot password?
Back
Submit
By providing my email, I consent to receiving messages from Stockhouse.
The Market Update
{{currentVideo.title}}
{{currentVideo.relativeTime}}
< Previous bulletin
Next bulletin >
A daily snapshot of everything
from market open to close.
{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}
{{currentVideo.intervieweeTitle}}
{{currentVideo.headline}}
{{currentVideo.link1Text}}
{{currentVideo.link2Text}}
< Previous
{{moreVideoText}}
Next >